Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
1 study found for:    14757686 [PUBMED-IDS]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Unknown † Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
Condition: Metabolic Syndrome
Interventions: Drug: Simvastatin;   Drug: Vytorin;   Drug: Placebo;   Drug: Ezetimibe
To Top

† Indicates status has not been verified in more than two years